ZEN 3365

Drug Profile

ZEN 3365

Alternative Names: ZEN 003365; ZEN3365

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zenith Epigenetics Corp
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Lymphoproliferative disorders; Solid tumours

Most Recent Events

  • 05 Jun 2017 Zenith Epigenetics has patent protection for its BET bromodomain inhibitors, in USA
  • 23 Sep 2014 Preclinical trials in Acute myeloid leukaemia in Canada (PO)
  • 23 Sep 2014 Preclinical trials in Lymphoproliferative disorders in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top